US Stock MarketDetailed Quotes
CYTO Altamira Therapeutics
- 1.1700
- -0.0100-0.85%
Close Jul 26 16:00 ET
- 1.1500
- -0.0200-1.71%
Post 17:57 ET
3.12MMarket Cap-130P/E (TTM)
1.2054High1.1200Low20.97KVolume1.2054Open1.1800Pre Close24.34KTurnover0.79%Turnover RatioLossP/E (Static)2.67MShares17.200052wk High-29.25P/B3.10MFloat Cap0.996052wk Low--Dividend TTM2.65MShs Float636800.0000Historical High--Div YieldTTM7.24%Amplitude0.9960Historical Low1.1600Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Altamira Therapeutics Stock Forum
Abdominal aortic aneurysm (AAA) is a serious medical condition characterized by the localized abnormal enlargement of the abdominal aorta, the major blood vessel supplying blood to the lower part of the body. When an AAA ruptures, it poses a life-threatening situation, with more ...
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
Altamira Therapeutics (Nasdaq:CYTO) has announced the publication of a preclinical study demonstrating effective treatment of abdominal aortic aneurysm (AAA) using their SemaPhore™ nanoparticles to deliver SOD2 mRNA. The study, conducted by researchers from Washington University and the U...
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
Altamira Therapeutics, under the stock ticker CYTO, has highlighted a newly published review supporting the use of betahistine for managing residual dizziness in benign paroxysmal positional vertigo (BPPV) patients. The review, appearing in Frontiers in Neurology, suggests that betahistine, which is commonly used outside the US, can significantl...
Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company focused on developing and commercializing RNA delivery technology for targets beyond the liver, recently announced the dissemination of positive results from its NASAR clinical trial with Bentri...
NEWS
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
NEWS
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
3 MINUTES AGO, 8:47 AM EDT
VIA GLOBENEWSWIRE
No comment yet